Boeltz, Sebastian
Amini, Poorya
Anders, Hans-Joachim
Andrade, Felipe
Bilyy, Rostyslav
Chatfield, Simon
Cichon, Iwona
Clancy, Danielle M.
Desai, Jyaysi
Dumych, Tetiana
Dwivedi, Nishant
Gordon, Rachael Ann
Hahn, Jonas
Hidalgo, Andrés
Hoffmann, Markus H.
Kaplan, Mariana J.
Knight, Jason S.
Kolaczkowska, Elzbieta
Kubes, Paul
Leppkes, Moritz
Manfredi, Angelo A.
Martin, Seamus J.
Maueröder, Christian
Maugeri, Norma
Mitroulis, Ioannis
Munoz, Luis E.
Nakazawa, Daigo
Neeli, Indira
Nizet, Victor
Pieterse, Elmar
Radic, Marko Z
Reinwald, Christiane
Ritis, Konstantinos
Rovere-Querini, Patrizia
Santocki, Michal
Schauer, Christine
Schett, Georg
Shlomchik, Mark Jay
Simon, Hans-Uwe
Skendros, Panagiotis
Stojkov, Darko
Vandenabeele, Peter
Berghe, Tom Vanden
van der Vlag, Johan
Vitkov, Ljubomir
von Köckritz-Blickwede, Maren
Yousefi, Shida
Zarbock, Alexander
Herrmann, Martin
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL134846)
Article History
Received: 18 May 2018
Revised: 5 November 2018
Accepted: 30 November 2018
First Online: 8 January 2019
Compliance with ethical standards
:
: FA is an inventor on issued patent no. 8,975,033 held by The Johns Hopkins University that covers “Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases” and serves as a consultant for Bristol-Myers Squibb. The other authors declare no competing interests.